GlassScriptPhysician profile
Yusuf Mathai
NPI 1588919799
$2,586.42
in general payments reported to CMS, 2019-2025
26 companies · $414 in 2025
The $414 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $160 · 2020: $110 · 2021: $164 · 2022: $204 · 2023: $1,117 · 2024: $416 · 2025: $414.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,948.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,947.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $341.45 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Corcept Therapeutics | $302.15 | 2023-2025 | Korlym |
| Pfizer INC. | $266.62 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $257.06 | 2023-2025 | |
| Lilly USA, LLC | $216.24 | 2021-2024 | Mounjaro |
| Takeda Pharmaceuticals U.S.A., INC. | $186.75 | 2020-2024 | Trintellix |
| Biohaven Pharmaceutical Holding Company LTD. | $151.17 | 2022 | |
| Dermira, INC. | $124.85 | 2019 | |
| Abbvie INC. | $122.39 | 2023-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $91.02 | 2023-2025 | Caplyta |
| Exact Sciences Corporation | $69.43 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Novartis Pharmaceuticals Corporation | $68.06 | 2023 | |
| Upsher-Smith Laboratories LLC | $56.80 | 2021-2022 | |
| Amarin Pharma, INC. | $43.46 | 2020 | |
| Harmony Biosciences LLC | $40.34 | 2023 | Wakix |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vbi Vaccine (Delaware) INC. | $38.00 | 2023 | Prehevbrio |
| Shire North American Group INC | $35.38 | 2019 | |
| Edwards Lifesciences Corporation | $28.59 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Glaxosmithkline, LLC. | $22.14 | 2023 | Trelegy Ellipta |
| Otsuka America Pharmaceutical, INC. | $21.99 | 2023 | Rexulti |
| Abbott Laboratories | $20.13 | 2022 | |
| Janssen Pharmaceuticals, INC | $19.68 | 2023 | Spravato |
| Xeris Pharmaceuticals, INC. | $19.11 | 2023 | Gvoke Hypopen |
| Mdd US Operations, LLC | $17.01 | 2020 | |
| Impel Pharmaceuticals INC. | $14.75 | 2023 | Trudhesa |
| Sanofi-Aventis U.S. LLC | $11.85 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yusuf Mathai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.